Newron Pharmaceuticals S.p.A.
SIX:NWRN.SW
9 (CHF) • At close October 22, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Newron Pharmaceuticals S.p.A. |
Symbool | NWRN.SW |
Munteenheid | CHF |
Prijs | 9 |
Beurswaarde | 173,330,100 |
Dividendpercentage | 0% |
52-weken bereik | 4.09 - 11.2 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Stefan Weber |
Website | https://www.newron.com |
An error occurred while fetching data.
Over Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (CHF)
Cijfers zijn in miljoenen (CHF)